JB Pharma Sees Robust Growth in Q1 with 14% Profit Rise

JB Chemicals & Pharmaceuticals Ltd has announced a significant 14% surge in its net profit, reaching Rs 202 crore in the June quarter.

This marks an increase from the Rs 177 crore profit reported in the same period last year, as per the company's regulatory filing.

The revenue for the first quarter grew by 9%, standing at Rs 1,094 crore, fueled by a robust domestic business and notable advancements in both acute and chronic segments, including ophthalmology.

According to CEO and Wholetime Director Nikhil Chopra, the domestic formulations business recorded a 14% growth, underpinned by a solid performance in various segments.

Meanwhile, the international business experienced a slight decline in revenue, falling to Rs 283 crore from Rs 290 crore in the year-ago period.

Looking ahead, Chopra expressed confidence in maintaining topline growth, optimizing costs, and enhancing organizational efficiencies, with a focus on domestic and CDMO segments.

(With inputs from agencies.)